IRulya Therapeutics Inc. (IRLA) stock
IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$39.80+0.02 (+0.05%)
Close on Nov 13, 2026Market cap $40.48MP/E –Yield –
IRulya Therapeutics cash
Cash and short-term investments held at the end of each period.
IRulya Therapeutics's cash was $105.20M at Sep 30, 2026. For fiscal 2025 it was $17.80M, down 56.4% from the year before. The highest annual figure on record is $133.80M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.80M | -56.4% |
| FY2024 | Dec 31, 2024 | $40.80M | -45.7% |
| FY2023 | Dec 31, 2023 | $75.10M | -16.7% |
| FY2022 | Dec 31, 2022 | $90.20M | -15.5% |
| FY2021 | Dec 31, 2021 | $106.80M | -20.2% |
| FY2020 | Dec 31, 2020 | $133.80M | +33.9% |
| FY2019 | Dec 31, 2019 | $99.90M | +39.3% |
| FY2018 | Dec 31, 2018 | $71.72M | +870.1% |
| FY2017 | Dec 31, 2017 | $7.39M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $105.20M | +300.0% |
| Q2 FY2026 | Jun 30, 2026 | $116.00M | +234.3% |
| Q1 FY2026 | Mar 31, 2026 | $18.20M | -42.4% |
| Q4 FY2025 | Dec 31, 2025 | $17.80M | -56.4% |
| Q3 FY2025 | Sep 30, 2025 | $26.30M | -45.0% |
| Q2 FY2025 | Jun 30, 2025 | $34.70M | -41.6% |
| Q1 FY2025 | Mar 31, 2025 | $31.60M | -53.4% |
| Q4 FY2024 | Dec 31, 2024 | $40.80M | -45.7% |
| Q3 FY2024 | Sep 30, 2024 | $47.80M | -42.5% |
| Q2 FY2024 | Jun 30, 2024 | $59.40M | -32.2% |
| Q1 FY2024 | Mar 31, 2024 | $67.80M | -24.8% |
| Q4 FY2023 | Dec 31, 2023 | $75.10M | -16.7% |
| Q3 FY2023 | Sep 30, 2023 | $83.20M | -11.8% |
| Q2 FY2023 | Jun 30, 2023 | $87.60M | -7.5% |
| Q1 FY2023 | Mar 31, 2023 | $90.20M | -1.4% |
| Q4 FY2022 | Dec 31, 2022 | $90.20M | -15.5% |
| Q3 FY2022 | Sep 30, 2022 | $94.30M | -17.6% |
| Q2 FY2022 | Jun 30, 2022 | $94.70M | -27.2% |
| Q1 FY2022 | Mar 31, 2022 | $91.50M | -37.8% |
| Q4 FY2021 | Dec 31, 2021 | $106.80M | -20.2% |
| Q3 FY2021 | Sep 30, 2021 | $114.40M | -17.0% |
| Q2 FY2021 | Jun 30, 2021 | $130.00M | -10.0% |
| Q1 FY2021 | Mar 31, 2021 | $147.00M | -9.5% |
| Q4 FY2020 | Dec 31, 2020 | $133.80M | +33.9% |
| Q3 FY2020 | Sep 30, 2020 | $137.80M | +14.4% |
| Q2 FY2020 | Jun 30, 2020 | $144.50M | +12.6% |
| Q1 FY2020 | Mar 31, 2020 | $162.40M | +175.3% |
| Q4 FY2019 | Dec 31, 2019 | $99.90M | +39.3% |
| Q3 FY2019 | Sep 30, 2019 | $120.50M | +341.5% |
| Q2 FY2019 | Jun 30, 2019 | $128.30M | +65.6% |
| Q1 FY2019 | Mar 31, 2019 | $59.00M | +1239.7% |
| Q4 FY2018 | Dec 31, 2018 | $71.72M | +870.1% |
| Q3 FY2018 | Sep 30, 2018 | $27.29M | – |
| Q2 FY2018 | Jun 30, 2018 | $77.47M | – |
| Q1 FY2018 | Mar 31, 2018 | $4.40M | – |
| Q4 FY2017 | Dec 31, 2017 | $7.39M | – |
See a number that looks wrong?